Mediterranean diet and age-related cognitive decline: A randomized clinical trial by Valls Pedret, Cinta et al.
Copyright 2015 American Medical Association. All rights reserved.
Mediterranean Diet and Age-Related Cognitive Decline
A Randomized Clinical Trial
Cinta Valls-Pedret, MSc; Aleix Sala-Vila, DPharm, PhD; Mercè Serra-Mir, RD; Dolores Corella, DPharm, PhD; Rafael de la Torre, DPharm, PhD;
Miguel Ángel Martínez-González, MD, PhD; Elena H. Martínez-Lapiscina, MD, PhD; Montserrat Fitó, MD, PhD; Ana Pérez-Heras, RD;
Jordi Salas-Salvadó, MD, PhD; Ramon Estruch, MD, PhD; Emilio Ros, MD, PhD
IMPORTANCE Oxidative stress and vascular impairment are believed to partly mediate
age-related cognitive decline, a strong risk factor for development of dementia.
Epidemiologic studies suggest that a Mediterranean diet, an antioxidant-rich cardioprotective
dietary pattern, delays cognitive decline, but clinical trial evidence is lacking.
OBJECTIVE To investigate whether a Mediterranean diet supplemented with antioxidant-rich
foods influences cognitive function compared with a control diet.
DESIGN, SETTING, AND PARTICIPANTS Parallel-group randomized clinical trial of 447
cognitively healthy volunteers from Barcelona, Spain (233 women [52.1%]; mean age, 66.9
years), at high cardiovascular risk were enrolled into the Prevención con Dieta Mediterránea
nutrition intervention trial fromOctober 1, 2003, through December 31, 2009. All patients
underwent neuropsychological assessment at inclusion and were offered retesting at the end
of the study.
INTERVENTIONS Participants were randomly assigned to aMediterranean diet supplemented
with extravirgin olive oil (1 L/wk), a Mediterranean diet supplemented with mixed nuts
(30 g/d), or a control diet (advice to reduce dietary fat).
MAIN OUTCOMES ANDMEASURES Rates of cognitive change over time based on a
neuropsychological test battery: Mini-Mental State Examination, Rey Auditory Verbal
Learning Test (RAVLT), Animals Semantic Fluency, Digit Span subtest from theWechsler Adult
Intelligence Scale, Verbal Paired Associates from theWechsler Memory Scale, and the Color
Trail Test. We usedmean z scores of change in each test to construct 3 cognitive composites:
memory, frontal (attention and executive function), and global.
RESULTS Follow-up cognitive tests were available in 334 participants after intervention
(median, 4.1 years). In multivariate analyses adjusted for confounders, participants allocated
to a Mediterranean diet plus olive oil scored better on the RAVLT (P = .049) and Color Trail
Test part 2 (P = .04) compared with controls; no between-group differences were observed
for the other cognitive tests. Similarly adjusted cognitive composites (mean z scores with
95% CIs) for changes above baseline of thememory composite were 0.04 (−0.09 to 0.18) for
the Mediterranean diet plus olive oil, 0.09 (−0.05 to 0.23; P = .04 vs controls) for the
Mediterranean diet plus nuts, and −0.17 (−0.32 to −0.01) for the control diet. Respective
changes from baseline of the frontal cognition composite were 0.23 (0.03 to 0.43; P = .003
vs controls), 0.03 (−0.25 to 0.31), and −0.33 (−0.57 to −0.09). Changes from baseline of the
global cognition composite were 0.05 (−0.11 to 0.21; P = .005 vs controls) for the
Mediterranean diet plus olive oil, −0.05 (−0.27 to 0.18) for the Mediterranean diet plus nuts,
and −0.38 (−0.57 to −0.18) for the control diet. All cognitive composites significantly (P < .05)
decreased from baseline in controls.
CONCLUSIONS AND RELEVANCE In an older population, a Mediterranean diet supplemented
with olive oil or nuts is associated with improved cognitive function.
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I ncreased lifespan in developed countries has resulted in agreatly increased frequency of age-related diseases, in-cluding Alzheimer disease,1 the most common type of
dementia.2 The economic and social burden of caring for per-
sons with dementia is increasing, and to date there are no ef-
fective pharmacologic agents to prevent or treat the disease3
or even its precursor stages.4 The view is emerging that to
achieveabenefitan interventionwould likelyneedtobestarted
in the preclinical stage, a situation that applies to a substan-
tial proportion of the elderly population worldwide.5 Hence,
identifying simple and effective interventions to prevent de-
mentia or delay its onset is a major public health priority.
Emerging evidence suggests an association between di-
etaryhabits andcognitiveperformance.6,7Oxidative stresshas
long been considered to play a major role in cognitive decline
andneurodegenerativedisorders.8Thus, it is plausible that, by
counteractingoxidativestress, antioxidant-rich foodsmightaf-
ford protection from neurodegenerative diseases. The Medi-
terranean diet is a plant-based, antioxidant-rich dietary pat-
tern reputed for its many health benefits.9 As previously
reviewed,10-12data fromlargeobservational studiessuggest that
increasingadherencetoMediterranean-typediets relates tobet-
ter cognitive function and a reduced risk of dementia. The ob-
servational studies analyzed, however, have many limita-
tions: dietary assessment performed usually only once before
outcome ascertainment, heterogeneity of Mediterranean diet
scores used to define dietary conformity, diversity of neuro-
psychological instrumentsusedtoassesscognitivefunction,and
residual confounding because individuals with high Mediter-
raneandietscores tendtohavehealthier lifestyles.All theserea-
sons highlight the need for randomized clinical trials.13
ThePrevención conDietaMediterránea (PREDIMED) ran-
domized clinical trial reported that, compared with a control
diet that consists of advice to reduce dietary fat, a Mediterra-
nean diet supplemented with either extravirgin olive oil or
mixednuts for nearly 5 years reduced the incidence of cardio-
vasculardiseasesby30%inolder individuals athigh risk.14The
Mediterraneandiet used in thePREDIMED trial in general and
the2supplemental foods inparticular are rich inbioactivephy-
tochemicals with antioxidant and anti-inflammatory
properties.15,16Thus, it isplausible that, togetherwith theover-
all dietary pattern, olive oil andnutsmight improveor at least
delayage-relatedcognitivedecline. In fact, anotherPREDIMED
substudy inwhich participants underwent neuropsychologi-
cal testing once at trial’s end reported improved cognition in
the 2Mediterranean diet arms, but the lack of baseline evalu-
ation precluded assessment of changes over time.17,18 To
address this issue, we evaluated cognitive changes with re-
peated measurements using a battery of standard neuropsy-
chological tests in a PREDIMED subcohort of cognitively
healthy individuals.
Methods
Participants
This clinical trial was conducted in a subcohort of the
PREDIMED trial (http://www.predimed.es). The protocol has
beendescribed indetail elsewhere.19The textof the studypro-
tocol can be found in the trial protocol in Supplement 1. For
this analysis, we asked 578 individuals consecutively re-
cruited in the Barcelona-North PREDIMED center fromOcto-
ber 1, 2003, through December 31, 2009, to undergo neuro-
psychological tests to assess cognition at 2 time points, as
previously described.20 Study participants weremen aged 55
to 80 years andwomen aged 60 to 80 years at high cardiovas-
cular risk but no cardiovascular disease at enrollment. Crite-
ria for eligibility were the presence of either type 2 diabetes
mellitus or at least 3 of 5 cardiovascular risk factors: smoking,
hypertension, dyslipidemia, overweight or obesity, and fam-
ilyhistoryof early-onset coronaryheartdisease.Exclusioncri-
teriawere prior cardiovascular disease, any severe chronic ill-
ness, substance abuse, illiteracy, and history of allergy or
intolerance to the supplemental foods olive oil or nuts. Exclu-
sion criteria specific for this substudy were difficulty in ex-
pression or comprehension of the Spanish language, depres-
sion (definedas a score>13on theHamiltonDepressionRating
Scale), and mild cognitive impairment (defined according to
thePetersendiagnostic criteria,which includememory symp-
toms, scores <1.5 SDs of the mean of a reference population
on an episodic memory test, preserved activities of daily liv-
ing, and absence of dementia).21
We obtained baseline and yearly data onmedical history,
medicationuse, lifestyle, andadiposity. Fasting venousblood
andmorning urine samples were obtained at baseline, 1 year,
3 years, 5 years, and the trial’s termination, whichever came
first.Thestudyprotocolwasconductedaccording to theguide-
lines laid down in the Declaration of Helsinki, and all proce-
dures were approved by the Comité Ético de Investigación
ClínicadelHospital ClínicdeBarcelona (ClinicalResearchEth-
ics Committee of Hospital Clínic of Barcelona). Written in-
formed consent was obtained from all participants.
Eligible candidates were randomly assigned to 1 of 3 in-
tervention groups: a Mediterranean diet supplemented with
extravirgin olive oil, aMediterraneandiet supplementedwith
mixed nuts, or a control diet (advice to reduce all dietary fat).
Randomization was performed centrally by means of a com-
puter-generated random-number sequence inblocksof50par-
ticipants balanced by sex and age (<70 and ≥70 years).19
Assessment of Risk Factors
Participants were considered to have diabetes, hyperlipid-
emia, orhypertension if theyhadapreviousdiagnosis of these
conditions or were treated with antidiabetic, cholesterol-
lowering, or antihypertensive agents, respectively. Anthropo-
metricmeasurementswere performed by standardmethods,
aspreviouslydescribed.19 Smokingstatuswascategorized into
never, current,orpast smokingaccording toself-reports.Physi-
cal activity was assessed with the validated Spanish version
of the Minnesota Leisure Time Physical Activity Question-
naire and expressed in minutes at a given metabolic equiva-
lent per day.22
Dietary Assessment and Nutritional Interventions
Dietarydatawerecollectedduringa face-to-face interviewwith
a trained dietitian using a validated 137-item food-frequency
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questionnaire.23Nutrient intakeswere computedusing Span-
ish food composition tables and adjusted for energy intake.
Candidates were randomly assigned to 1 of 3 interventions:
Mediterraneandiet plusoliveoil,Mediterraneandiet plusnuts,
or control diet. Quarterly sessions were scheduled for the 2
Mediterranean diet groups; in them, they were educated on
how to follow the Mediterranean diet and received supple-
mental foods at no cost. Olive oil (1 L/wk)was provided to one
group and 30 g/d of mixed nuts (15 g of walnuts, 7.5 g of ha-
zelnuts, and 7.5 g of almonds) to the other group. During the
first 3 years of the trial, participants in the control diet group
werescheduled foryearlyvisits inwhich theyweregivena leaf-
let explaining the low-fat diet. The realization that the more
infrequentvisits for this groupmightbea limitationof the trial
prompted a protocol amendment in October 2006. Thereaf-
ter, participants allocated to the control diet received person-
alizedadvice andgroup sessionswith the same frequencyand
intensity as those in theMediterranean diet groups. In them,
participantswereeducatedonhowto followa low-fatdiet and
received small nonfood gifts. In each session, a validated 14-
itemscreenerof adherence to theMediterraneandietwasused
to track diet changes.24 Neither energy restriction nor in-
creased physical activity was advised for any treatment arm.
Evaluation of Cognitive Function
An experienced neuropsychologist (C.V.-P.) whowasmasked
to the participants’ diet and cardiovascular risk factors con-
ducted the cognitive examinations.Neuropsychological tests
were performed at baseline and repeated at the date closest
to the study’s termination that was most convenient for par-
ticipants. Thus, follow-up timewas not the same for all study
participants.The instrumentsusedwere theMini-Mental State
Examination to assess global cognitive function, the Rey Au-
ditory Verbal Learning Test (RAVLT) to rate immediate (sum
of words recalled on the 5 learning trials) and delayed epi-
sodic verbal memory, and the verbal paired associates test, a
subtest of Wechsler Memory Scale, to evaluate episodic
memory performance. While recruitment was ongoing, we
added tests to assess changes in language and frontal func-
tions aswell. To this end,we included the animal fluency test
to evaluate semantic fluency, the Digit Span subtest of the
WechslerAdult IntelligenceScale toassess immediatememory
(forward digits) and working memory (backward digits), and
the Color Trail Test (parts 1 and 2) to measure attention, vi-
suomotor speed, and cognitive flexibility.
Participants’ raw test changes were standardized to z
scores, and 3 composite scores of cognitive functionwere cal-
culated for each participant. First, thememory composite in-
cluded themean standardized individual change scores of the
RAVLT and Wechsler Memory Scale paired associates sub-
test. The second composite score related to frontal functions,
including tests measuring attention, cognitive flexibility and
workingmemory, andwasconstructedbyaveraging standard-
izedchangescoresof theWechslerAdult IntelligenceScaleDigit
Figure 1. FlowDiagram of the Study
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Backward Test and Color Trail Test (parts 1 and 2). Third, a
global cognition composite was generated by computing the
meanstandardizedchangesof all neuropsychological tests, in-
cluding theMini-Mental State examination. These 3 compos-
ite scores were prespecified as the primary outcomes of the
study. Incident cases of mild cognitive impairment were re-
corded as well.
Laboratory Determinations
To determine adherence to supplemental foods,wemeasured
urinary hydroxytyrosol (the main phenolic compound in ex-
travirgin olive oil) and plasma proportions of α-linolenic acid
(a fatty acid characteristic ofwalnuts) at baseline and the clos-
est time point to the second cognitive evaluation in a random
subsample of participants, as described.14 The APOE ε4 geno-
typewasdeterminedwith themethodofHixsonandVernier.25
Statistical Analyses
Baseline imbalances in demographic variables and cardiovas-
cular risk factors among treatment groups were assessed by
analysis of variance (ANOVA)or χ2 tests, as appropriate.Differ-
ences between the participantswhowithdrew fromand those
whoremained inthestudywereassessedbythe t testorχ2 tests,
as appropriate. Baseline and postintervention (the time point
closest to the second cognitive evaluation) food and nutrient
consumption and biomarkers of adherence were assessed by
ANOVA. Between-group differences in baseline neuropsycho-
logical test scores were assessed by ANOVA and in addition by
analysisof covariance (ANCOVA)withadjustment for sex,base-
lineage, yearsof education,APOEε4genotype, smoking,body
mass index, energy intake, physical activity, diabetes, hyper-
lipidemia, the ratioof total cholesterol tohigh-density lipopro-
tein cholesterol, statin treatment,hypertension, anduseof an-
ticholinergicdrugs.Postinterventionchanges foreachcognitive
test and test composites were assessed by ANOVA and addi-
tionallybyANCOVA,adjustingfor thevariables listedaboveplus
follow-uptime.Between-groupdifferences in incidentmildcog-
nitive impairmentwere analyzed by logistic regression adjust-
ing for the confounders listed above. Bonferroni post hoc tests
were used for all comparisons. Statistical significance was set
at the P < .05 level. Analyses were performed using SPSS sta-
tistical software, version 16.0 (SPSS Inc).
Results
Participants
Thebaselineneuropsychological evaluationwascompletedby
447 participants, but 113 (25.3%) refused to undergo a second
procedure or abandoned the study for different reasons
(Figure1).Nosignificantdifferenceswereobservedbetweenpar-
ticipants who withdrew from and those who remained in the
study in terms of age, sex, years of education, or cardiovascu-
lar risk factors (data not shown). However, there were more
APOE ε4 alleles (24.8% and 15.6%, respectively; P = .004) and
worse cognitive scores on the Mini-Mental State Examination
Table 1. Baseline Characteristics of Participants by Study Groupa
Characteristic
Mediterranean
Diet Plus
Extravirgin
Olive Oil
(n = 127)
Mediterranean
Diet Plus
Nuts
(n = 112)
Control Diet
(n = 95) P Valueb
Men 60 (47.2) 58 (51.8) 46 (48.4) .77
Age, mean (SD), y 67.9 (5.4)c 66.7 (5.3) 65.5 (5.8) .005
Body mass index, mean (SD) 28.5 (3.3) 28.4 (3.2) 28.5 (3.3) .95
Educational level, mean (SD), y 6.8 (3.0) 7.6 (3.3) 7.1 (2.8) .13
Married 101 (79.5) 89 (79.5) 74 (77.9) .47
Family history of early-onset CHD 40 (31.5) 23 (20.5) 32 (33.7) .07
Ever smoker 54 (42.5) 47 (42.0) 44 (46.3) .79
Dyslipidemia 96 (75.6) 83 (74.1) 68 (71.6) .80
Total cholesterol, mean (SD), mg/dL 220.7 (32.1)c 217.1 (37.6) 209.4 (33.6) .051
LDL-C, mean (SD), mg/dL 136.4 (31.2) 137.0 (33.7) 129.3 (28.4) .15
HDL-C, mean (SD), mg/dL 57.5 (16.5)c 54.7 (13.9) 51.6 (12.0) .01
Triglycerides, mean (SD), mg/dL 134.4 (99.5) 128.7 (65.9) 146.1 (87.7) .34
Ratio of total cholesterol to HDL-C 4.1 (0.99) 4.1 (0.95) 4.2 (0.97) .54
Use of hypolipidemic drugs 67 (52.8) 53 (47.3) 47 (49.5) .70
Hypertension 98 (77.2) 77 (68.8) 73 (76.8) .26
Use of antihypertensive agents 86 (67.7) 71 (63.4) 63 (66.3) .78
Type 2 diabetes mellitus 70 (55.1) 66 (58.9) 48 (50.5) .48
Use of antidiabetic medication 34 (26.8) 41 (36.6) 36 (37.9) .20
Use of anticholinergic drugs 20 (15.7) 13 (11.6) 15 (15.8) .59
Physical activity, mean (SD), MET-min/d 541 (358) 554 (339) 516 (349) .73
APOE ε4 genotype 24 (18.9) 14 (12.5) 14 (14.7) .38
Hamilton Depression Rating Scale score,
mean (SD)
2.1 (2.5) 2.2 (2.6) 2.4 (2.6) .68
Abbreviations: CHD, coronary heart
disease; HDL-C, high-density
lipoprotein cholesterol;
LDL-C, low-density lipoprotein
cholesterol; MET-min, minutes at a
givenmetabolic equivalent level
(units of energy expenditure in
physical activity, 1 MET-min roughly
equivalent to 1 Kcal).
SI conversion factors: To convert
cholesterol values to millimoles per
liter, multiply by 0.0259; triglyceride
levels to millimoles per liter, multiply
by 0.0113.
a Data are presented as number
(percentage) of patients unless
otherwise indicated.
bP value for comparisons across
groups with the Pearson χ2 test for
categorical variables or 1-way
analysis of variance for continuous
variables.
c Significantly different from control
diet group (Bonferroni post hoc
test).
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(27.7 and 28.1, respectively; P = .006) and Wechsler Memory
Scale (14.2 and 15.1, respectively; P = .02) among participants
whowithdrew from the study comparedwith thosewho com-
pleted the study. Dropouts were unevenly distributed among
groups (18.1% Mediterranean diet plus olive oil, 28.8% Medi-
terranean diet plus nuts, and 34.5% control diet; P = .004).
Table 1 gives the baseline demographic and clinical char-
acteristics for the 334 participants who completed the study
(median follow-up, 4.1 years; range, 1.0–8.8 years). Themean
age of the participants was 66.8 years, and 170 (50.9%) were
women. The characteristics of participants in the 3 interven-
tion groups were well balanced except for age and lipid val-
ues because participants in theMediterranean diet plus olive
oil groupwere amean of 2 years older than those allocated to
the control group, and total andhigh-density lipoprotein cho-
lesterol levels were lower in the control group.
Dietary Changes
Participants assigned to the Mediterranean diet plus olive
oil group significantly increased consumption of extravirgin
olive oil while reciprocally decreasing consumption of com-
mon olive oil. Expectedly, those allocated to the Mediterra-
nean diet plus nuts group increased nut consumption
(eTable 1 in Supplement 2). The main nutrient changes in
the Mediterranean diet groups reflected the fat composition
of the supplemental foods because energy supplied as
monounsaturated and polyunsaturated fatty acids signifi-
cantly increased in the Mediterranean diet plus olive oil
and Mediterranean diet plus nuts groups, respectively
(Table 2).
Participants in the 3 groups reported similar baseline ad-
herence to theMediterraneandiet, as assessed by the 14-item
screener. Compared with the control group, both Mediterra-
nean diet groups had increased adherence to the Mediterra-
neandiet at the endof follow-up. Changes in biomarkerswere
mean increases of 0.19% for plasma α-linolenic acid in the
Mediterranean diet plus nuts group and of 49.6 μg/L in uri-
nary hydroxytyrosol in the Mediterranean diet plus olive oil
group, indicatinggoodadherencewith thesupplemental foods
(eTable 2 in Supplement 2).
Table 2. Baseline Energy and Nutrient Consumption and Changes by Study Groupa
Variable
Mean (95% CI)
P Valuea
Mediterranean Diet
Plus Extravirgin Olive Oil
(n = 127)
Mediterranean Diet
Plus Nuts
(n = 112)
Control Diet
(n = 95)
Energy, kcal
Baseline 2453 (2339 to 2566) 2505 (2403 to 2608) 2398 (2275 to 2521) .44
Change −309 (−411 to −206) −271 (−371 to −171) −345 (−456 to −233) .64
Energy from protein, %
Baseline 17.0 (16.5 to 17.5) 16.5 (16.0 to 17.0) 16.6 (16.0 to 17.1) .34
Change 0.52 (0.10 to 0.95) 0.31 (−0.14 to 0.75) 0.10 (−0.51 to 0.71) .48
Energy from carbohydrate, %
Baseline 41.8 (40.5 to 43.0) 41.4 (40.3 to 42.6) 41.8 (40.4 to 43.2) .90
Change −4.59 (−5.72 to −3.47) −5.01 (−6.05 to −3.97)b −2.61 (−4.03 to −1.18) .02
Fiber, g/1000 kcal
Baseline 12.3 (11.7 to 13.0) 11.6 (11.0 to 12.2) 11.7 (10.9 to 12.4) .22
Change 0.14 (−0.43 to 0.71) 0.82 (0.35-1.29) −0.07 (−0.68 to 0.54) .07
Energy from fat, %
Baseline 38.3 (37.2 to 39.4) 38.7 (37.7 to 39.7) 38.2 (36.9 to 39.4) .79
Change 3.51 (2.46 to 4.55) 4.52 (3.52 to 5.52)b 1.97 (0.69 to 3.25) .008
Saturated fatty acids, %
Baseline 10.2 (9.8 to 10.6) 10.4 (10.0 to 0.8) 10.1 (9.6 to 10.6) .61
Change −0.29 (−0.64 to 0.05) −0.59 (−0.89 to −0.28) −0.20 (−0.69 to 0.29) .33
Monounsaturated fatty acids, %
Baseline 18.7 (18.1 to 19.3) 18.6 (18.0 to 19.3) 18.8 (18.0 to 19.6) .95
Change 3.66 (3.00 to 4.33)b 3.40 (2.68 to 4.12) 2.17 (1.32 to 3.03) .02
Polyunsaturated fatty acids, %
Baseline 6.1 (5.7 to 6.4) 6.4 (6.0 to 6.8) 6.1 (5.7 to 6.5) .30
Change −0.02 (−0.44 to 0.40) 1.49 (1.09 to 1.88)c −0.14 (−0.61 to 0.33) <.001
Cholesterol, mg
Baseline 413 (393 to 434) 405 (384 to 426) 399 (374 to 425) .66
Change −48.0 (−68.1 to −28.0) −41.0 (−60.3 to −21.7) −71.2 (−92.9 to −49.5) .12
a P value for comparisons across groups with 1-way analysis of variance.
b Significantly different from control group (Bonferroni post hoc test).
c Significantly different from the other intervention groups (Bonferroni post hoc test).
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Cognitive Function
The interventions had no significant effect on depression
scores. Mean changes after theMediterranean diet plus olive
oil, Mediterranean diet plus nuts, and control diet were 0.1,
−1.6, and 0.3, respectively (P = .49).
eTable3 inSupplement2gives thebaselinecognitivescores
and changes at the end of the trial. Table 3 gives the fully ad-
justed values for the same variables. No baseline differences
existed among study groups in the adjusted model. Im-
proved 4-year scores in the 2 RAVLTs were observed in all
groups, with significant differences in the RAVLT for the par-
ticipants in theMediterranean diet plus olive oil group vs the
control group. Participants in theMediterranean diet plus ol-
ive oil group also had improved scores on the Color Trail Test
part 1, but the adjusted changes were not significant com-
paredwith those in the control group (P = .06). TheColorTrail
Test part 2 scores worsened in all groups, although less in the
Mediterraneandiet plusoliveoil group,withadjustedchanges
significantlydifferent fromthose in thecontrol group (Table3).
Figure 2 and Table 4 report adjusted changes in compos-
ite scores for memory, frontal functions, and global cogni-
tion. Table 4 also reports unadjusted values, which differed
little fromthose in the fully adjustedmodel. Participants in the
control group had a significant decrease from baseline in all
composites. Compared with the control group, the memory
composite improved significantly in the Mediterranean
diet plus nuts group, whereas the frontal and global cogni-
tion composites improved in the Mediterranean diet plus ol-
ive oil group. Figure 2 also shows that the changes for the 2
Mediterraneandietarms ineachcompositeweremore likeeach
other than when comparing those of the individual Mediter-
ranean diet arms with the control arm.
Table 3. Baseline Cognitive Test Scores and Changes by Study Group
Variable
Mean (95% CI)
P Valuea
Mediterranean Diet
Plus Extravirgin
Olive Oil
(n = 127)
Mediterranean Diet
Plus Nuts
(n = 112)
Control Diet
(n = 95)
MMSEb
Baseline 28.01 (27.79 to 28.24) 28.11 (27.87 to 28.35) 28.38 (28.12 to 28.65) .10
Change 0.16 (−0.12 to 0.44) −0.07 (−0.36 to 0.23) −0.26 (−0.57 to 0.06) .15
RAVLT, total learningb
Baseline 39.31 (37.92 to 40.70) 39.46 (37.98 to 40.94) 39.24 (37.63 to 40.85) .98
Change 4.50 (3.24 to 5.77)c 4.26 (2.91 to 5.60) 2.10 (0.64 to 3.57) .04
RAVLT, delayed recallb
Baseline 6.61 (6.09 to 7.13) 6.48 (5.93 to 7.03) 6.37 (5.77 to 6.96) .83
Change 1.47 (1.02 to 1.92) 1.80 (1.32 to 2.28) 0.95 (0.43 to 1.47) .06
Paired associatesb
Baseline 15.25 (14.69 to 15.82) 15.25 (14.65 to 15.85) 14.89 (14.24 to 15.54) .66
Change 0.25 (−0.33 to 0.83) 0.41 (−0.21 to 1.03) −0.09 (−0.76 to 0.58) .56
Verbal fluencyd
Baseline 18.44 (17.18 to 19.70) 20.33 (18.86 to 21.79) 19.02 (17.53 to 20.51) .16
Change 0.53 (−0.78 to 1.84) −1.51 (−3.08 to 0.06) 0.30 (−1.27 to 1.87) .13
Digit Span Forwardd
Baseline 5.33 (5.03 to 5.63) 5.20 (4.85 to 5.56) 5.23 (4.89 to 5.57) .85
Change 0.11 (−0.16 to 0.38) 0.36 (−0.01 to 0.73) −0.08 (−0.40 to 0.25) .28
Digit Span Backwardd
Baseline 3.76 (3.49 to 4.02) 3.83 (3.52 to 4.14) 3.95 (3.66 to 4.25) .63
Change 0.25 (−0.10 to 0.59) 0.34 (−0.12 to 0.81) −0.24 (−0.64 to 0.17) .14
Color Trail Test part 1d,e
Baseline 62.60 (56.29 to 68.91) 61.15 (53.56 to 68.74) 57.00 (49.61 to 64.38) .53
Change −5.77 (−11.25 to −0.28) 2.48 (−5.29 to 10.26) 4.53 (−2.11 to 11.17) .045
Color Trail Test part 2d,e
Baseline 136.55 (123.19 to 149.90) 131.59 (115.13 to 148.05) 129.99 (114.39 to 145.60) .81
Change 5.66 (−10.23 to 21.55)c 24.23 (1.36 to 47.10) 37.56 (18.14 to 56.97) .045
Abbreviations: MMSE, Mini-Mental State Examination; RAVLT, Rey Auditory
Verbal Learning Test.
a P value by analysis of covariance adjusted for sex, baseline age, years of
education, marital status, APOE ε4 genotype, ever smoking, baseline body
mass index, energy intake, physical activity, type 2 diabetes mellitus,
hyperlipidemia, ratio of total cholesterol to HDL-C, statin treatment,
hypertension, use of anticholinergic drugs, and time of follow-up (not in
baseline, only in change).
bMeasured in 334 participants (127, 112, and 95 participants, respectively).
c Significantly different from control group (Bonferroni post hoc test).
dMeasured in 96 participants (41, 25, and 30 participants, respectively).
e Lower scores indicate improvement.
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At the end of follow-up,we identified 37 cases of incident
mild cognitive impairment: 17 (13.4%) in the Mediterranean
diet plusoliveoil group,8 (7.1%) in theMediterraneandiet plus
nuts group, and 12 (12.6%) in the control group (adjusted
P = .28). Nodementia caseswere documented in participants
completing follow-up.
Discussion
The PREDIMED study is a 5-year randomized clinical trial of
nutrition intervention with the Mediterranean diet vs a con-
trol diet for primary cardiovascular prevention in older indi-
viduals at high cardiovascular risk.14 In a PREDIMED sub-
study, we assessed cognitive performance by various
neuropsychological tests at baseline and after a median fol-
low-up of 4.1 years. Results revealed cognitive improvement
in participants allocated the Mediterranean diet and cogni-
tive decline in those allocated the control diet. The benefit of
the Mediterranean diet was independent of sex, age, energy
intake, and cognition-related variables, including educa-
tional level,APOEε4genotype, andvascular risk factors.These
findings are novel because, to our knowledge, no prior long-
term clinical trial has assessed cognitive changes in response
to dietary patterns.
Our results extend those of prior PREDIMED substudies
wherein cognitive performancewas better after the interven-
tion in the 2 Mediterranean diet groups17 or in theMediterra-
nean diet plus olive oil group,18 but changes over time were
not assessed. Inasmuch as the main food changes were in-
creased intakes of the supplemental foods olive oil and nuts
in the corresponding Mediterranean diet groups, our find-
ings also concur with those of the cross-sectional analysis at
baseline of the same cohort, in which higher consumption of
olive oil and walnuts was independently related to better
cognition.20 The data are consistent as well with large obser-
vational studies10-12 providing longitudinal evidenceof amod-
erate protective effect of the Mediterranean diet against cog-
nitive decline and Alzheimer disease. Our findings, however,
derive froma randomized clinical trialwithbaseline andpost-
intervention assessments, thus providing a stronger level of
scientific evidence.13
In our study, participants allocated to the Mediterranean
diet plus nuts had improvement in the memory composite
compared with those ascribed the control diet. Thus far, sci-
entific evidence is limitedon theassociationbetweennut con-
sumption and cognition. Two observational studies, the
Doetinchem Cohort26 and the Nurses’ Health Study,27 found
that long-termnut consumptionwas related to overall cogni-
tion at older age but not to cognitive decline during follow-up
for 5 to 6 years. On the other hand, a randomized clinical trial
inyoungadults foundnoeffect ofwalnut supplementation for
8 weeks on cognitive function.28 Results from experimental
studies29,30havealso linkeddietarysupplementationwithnuts,
particularlywalnuts, to improved cognitive outcomes in aged
animals. A prior PREDIMED substudy31 with a larger sample
size indicated that the Mediterranean diet plus nuts reduced
incidentdepressionamongdiabetic participants. Inour study,
with lower statistical power, we observed no effect of the in-
tervention on depression scores.
Participants in theMediterraneandiet plus olive oil group
had improved frontal function and global cognition compos-
ites in our study. There is also little evidence on the associa-
tion betweenolive oil consumption and cognition. In thepro-
spective Three-City Study in France,32 a weak association
between increased olive oil intake and risk of cognitive de-
cline during a 4-year follow-upwas described. Greater intake
ofmonounsaturated fatty acids, abundant in olive oil, also re-
lated to better cognitive function in the Italian Longitudinal
Study onAging after an 8-year follow-up.33 In the same line, a
PREDIMED substudy18 reported decreased rates of mild cog-
nitive impairment in participants allocated to the Mediterra-
nean diet plus olive oil compared with those in the control
group.
The beneficial effect ofMediterranean diets on cognition
probably stems from the abundance of antioxidants and anti-
inflammatory agents that they provide. The supplemental
foods,extravirginoliveoil andnuts, areparticularly rich inphe-
nolic compounds15,16 that might counteract oxidative pro-
cesses in the brain, leading to neurodegeneration. Polyphe-
Figure 2. Changes in Cognitive FunctionMeasuredWith Composites
by Intervention Group
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Error bars indicate 95% CIs. P values by analysis of covariance were adjusted for
sex, baseline age, years of education, marital status, APOE ε4 genotype, ever
smoking, baseline bodymass index, energy intake, physical activity, type 2
diabetes mellitus, hyperlipidemia, ratio of total cholesterol to high-density
lipoprotein cholesterol, statin treatment, hypertension, use of anticholinergic
drugs, and time of follow-up, with the Bonferroni post hoc test. For each
cognitive composite, the changes between the 2Mediterranean arms were not
statistically different (P >.99 for all). The changes for memory between the
Mediterranean diet plus olive oil and control groups and for frontal and global
cognition between theMediterranean diet plus nuts and control groups had
values of P < .25.
a P < .05.
bP < .01.
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nols can ameliorate neurologic health by additional
mechanisms, including improved cerebrovascular blood flow,
modulationofneuronal signaling, enhanced synthesis ofneu-
rotrophic factors, and stimulation of neurogenesis.34 Diabe-
tes is an established linkwith cognitive decline, and a variety
of polyphenols alsodisclose anantidiabetic effect.35 In this re-
gard, results fromthe cross-sectional evaluation at baselineof
thepresent cohort,wherebyurinarypolyphenol excretion (an
objectivebiomarkerof intake)was linearlyassociatedwithbet-
termemory scores,20 reinforce the notion that phenolic com-
pounds protect brain function.6 On the other hand, nuts, par-
ticularlywalnuts given inonearmof the trial, contain sizeable
amounts of α-linolenic acid, the vegetable ω3 fatty acid. Ad-
ministrationof this fatty acidhasbeen found toenhancebrain
plasticity and exert an antidepressant effect in experimental
animals.36
Aconsistentbodyofevidencesupportsahigheffectofvas-
cular risk factors on cognitive decline anddementia37; hence,
another mechanism through which the Mediterranean diet
might promote brain health is vascular improvement. Brain
magnetic resonance imaging investigationshavefoundastrong
beneficial effect of high adherence to theMediterranean diet
on white matter hyperintensities38 and subclinical brain
infarcts.39 Furthermore, prospective studies have suggested
that the Mediterranean diet40,41 and the use of olive oil42 re-
duce the incidence of stroke. In the PREDIMED study,14 the 2
Mediterraneandiet interventions reduced the incidenceof car-
diovascular diseases by 30% compared with the control diet,
whereas the risk of stroke was reduced by 34% in the Medi-
terraneandiet plus olive oil group andby49% in theMediter-
ranean diet plus nuts group. Besides vascular brain damage,
other strong associations of cognitive impairment andAlzhei-
merdisease arehypertension37 anddiabetes,43 and thePRED-
IMEDMediterraneandiets alsohadabeneficial effect onblood
pressure44 and diabetes risk.45
There are still other possiblemechanismsof brain protec-
tion byMediterraneandiets, such as increase of neurotrophic
factors related to neurotransmission, synaptic plasticity, and
elimination of β-amyloid from the brain. Thus, a report from
a 3-year PREDIMED substudy46 found increased plasma con-
centrations of brain-derived neurotrophic factor in theMedi-
terraneandiet plusnutsgroup.Finally,anexperimental study47
found that oleocanthal, a phenolic component of extravirgin
oliveoil, enhancesbrainβ-amyloidclearance, suggestinga link
between olive oil consumption and reduced risk of Alzhei-
mer disease.
Our study has limitations. First, this is a post hoc analysis
of a subsample in a larger clinical trial that was not specifi-
cally designed to examine cognition. Second, the overall
sample size is small, and the subsample receiving tests of fron-
tal functions and language is even smaller. Nonetheless, the
results of all composite cognitive scoreswere statistically sig-
nificant in favor of theMediterranean diets, with little differ-
ences before and after adjusting for confounders. Third, be-
cause of our differential results for theMediterranean diet on
cognitive composites, depending on whether it included ol-
ive oil or nuts, it is difficult to precisely delineatewhat part of
thedietwasassociatedwithpreventingcognitivedecline.How-
ever, changes in the 2 Mediterranean diet groups were more
like eachother thanwhen comparedwith those in the control
Table 4. Baseline Cognitive FunctionMeasuredWith Composites and Changes by Intervention Group
Variable
Mean (95% CI)
P Value
Mediterranean Diet
Plus Extravirgin
Olive Oil
Mediterranean Diet
Plus Nuts Control Diet
Memorya
Unadjusted modelb
Baseline −0.06 (−0.02 to 0.08) 0.04 (−0.12 to 0.20) 0.04 (−0.14 to −0.23) .56
Change 0.04 (−0.10 to 0.17) 0.08 (−0.06 to 0.22) −0.14 (−0.29 to 0.004) .08
Fully adjusted modelc
Baseline 0.02 (−0.11 to 0.15) 0.013 (−0.13 to 0.16) −0.04 (−0.20 to −0.11) .82
Change 0.04 (−0.09 to 0.18) 0.09 (−0.05 to 0.23)d −0.17 (−0.32 to −0.01) .04
Frontal Cognitione
Unadjusted modelb
Baseline 0.06 (−0.10 to 0.23) 0.02 (−0.16 to 0.21) −0.10 (−0.33 to 0.12) .41
Change 0.23 (0.07 to 0.38)d −0.02 (−0.27 to 0.22) −0.28 (−0.53 to −0.03) .002
Fully adjusted modelc
Baseline −0.06 (−0.25 to 0.13) 0.04 (−0.20 to 0.27) 0.12 (−0.11 to −0.34) .50
Change 0.23 (0.03 to 0.43)d 0.03 (−0.25 to 0.31) −0.33 (−0.57 to −0.09) .003
Global Cognitione
Unadjusted modelb
Baseline 0.06 (−0.06 to 0.18) 0.21 (0.06 to 0.36) 0.22 (0.06 to 0.39) .17
Change 0.05 (−0.08 to 0.18)d −0.06 (−0.24 to 0.11) −0.36 (−0.56 to −0.15) .001
Fully adjusted modelc
Baseline −0.07 (−0.17 to 0.04) −0.05 (−0.16 to 0.06) −0.07 (−0.19 to 0.05) .97
Change 0.05 (−0.11 to 0.21)d −0.05 (−0.27 to 0.18) −0.38 (−0.57 to −0.18) .005
a Measured in 334 participants (127,
112, and 95 participants,
respectively).
b Comparisons across groups by
1-way analysis of variance.
c Comparisons across groups by
analysis of covariance adjusted for
sex, baseline age, years of
education, marital status, ApoE4
genotype, ever smoking, baseline
bodymass index, energy intake,
physical activity, diabetes mellitus,
hyperlipidemia, ratio of total
cholesterol to high-density
lipoprotein cholesterol, statin
treatment, hypertension, use of
anticholinergic drugs, and time of
follow-up (not in baseline, only in
change).
d Significantly different from control
group (Bonferroni post hoc test).
e Measured in 96 participants (41, 25,
and 30 participants, respectively).
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arm, from which it can be inferred that the 2 Mediterranean
dietswereprotective. Fourth,wehad losses to follow-up, pre-
dominantly in the control group, probably because partici-
pants did not receive food incentives. Nevertheless, dropout
rates per group followed a pattern similar to that of the main
trial14 andwere not unexpected given the older age of partici-
pants and the trial’s duration. Fifth, participants who with-
drew had worse baseline cognition and more APOE ε4 geno-
types than completers, thus being more likely to disclose
cognitive impairment during follow-up. The fact that there
were more dropouts in the control group suggests a bias to-
ward a benefit in this group. Sixth, given the long recruit-
mentperiod, intervalsof follow-upcognitiveassessmentswere
unavoidably unequal. For this reason, follow-up timewas en-
teredas a confounder in themultivariablemodels. Finally, our
cohortwas selected forhighvascular risk,whichpreventsgen-
eralizing the results to the average elderly population. There
are also strengths to our study, such as the randomized de-
sign, longdurationof the intervention, assessment of diet ad-
herence by objective biomarkers, and use of a comprehen-
sivebatteryof standardizedneuropsychological tests to assess
cognitive function.
Conclusions
Our results suggest that in an older population a Mediterra-
nean diet supplemented with olive oil or nuts may counter-
act age-related cognitive decline. The lack of effective treat-
ments for cognitive decline and dementia points to the need
ofpreventive strategies todelay theonset and/orminimize the
effectsof thesedevastatingconditions.Thepresent resultswith
the Mediterranean diet are encouraging, but further investi-
gation is warranted.
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